EUVIMEDEUVIMED entdecken
Delphi-StudieOpen Access

Delphi Consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP) on the management of severe asthma in children and adolescents

Delphi-Konsens der Italian Society of Pediatric Allergy and Immunology (SIAIP) zum Management von schwerem Asthma bei Kindern und Jugendlichen

Michele Miraglia Del Giudice, Gianluigi Marseglia, Sara Manti, Filippo Favuzza, Maria Angela Tosca, Giorgio Ciprandi, Amelia Licari

Multidisciplinary Respiratory Medicine · 20.07.2026 · 21 (Vol. 21 (2026)) · 1095

DOI: 10.5826/mrm.2026.1095 ↗

Auf einen Blick

50 Expert:innen erreichten für alle 27 Aussagen Konsens zum Management von schwerem pädiatrischem Asthma. Im Fokus standen die Auswahl biologischer Therapien und die systematische Verlaufskontrolle.

Fragestellung

Es sollte ein Expertenkonsens zum Management von schwerem Asthma bei Kindern und Jugendlichen mit Schwerpunkt auf biologischer Therapie, Monitoring und Ansprechen erstellt werden.

Methode

Modifizierter Delphi-Prozess mit 50 pädiatrischen Asthma-Expert:innen; 27 Aussagen zu Epidemiologie, Pathophysiologie, Biomarkern, biologischen Therapien, Monitoring und Ansprechen.

Ergebnisse

Alle 27 Aussagen erreichten Konsens (Zustimmung 82-100 %; mittlere Scores 4,1-4,9). Konsens u. a. zu endotypbasierter Therapie, Typ-2-Inflammation, Biomarkern und COMSA.

Schlussfolgerung der Autor:innen

Der Delphi-Konsens liefert von Expert:innen gestützte, evidenzbasierte Empfehlungen für das Management von schwerem pädiatrischem Asthma mit personalisierter Biologikawahl und standardisiertem Monitoring.

Kernaussagen

  • Alle 27 Aussagen erreichten Konsens
  • Biologika: Omalizumab, Mepolizumab, Dupilumab, Tezepelumab
  • Biomarker und COMSA wurden für Monitoring und Ansprechen betont

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Delphi-Studie in der Zeitschrift Multidisciplinary Respiratory Medicine, erschienen am 20.07.2026. Verfasst von Michele Miraglia Del Giudice und 6 weiteren Autor:innen. Beteiligte Einrichtung: Università della Campania. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe asthma affects approximately 3-5% of the pediatric asthmatic population and is associated with substantial clinical, economic, and psychosocial burdens. Despite major advances in biological therapies, standardized guidance for their optimal use in children and adolescents remains limited.

Objective

To establish experts’ consensus on the management of severe pediatric asthma through a Delphi process promoted by the Italian Society of Pediatric Allergy and Immunology (SIAIP), with particular focus on biological therapy selection, monitoring, and response assessment.

Methods

A modified Delphi process involving 50 pediatric asthma experts was conducted. Twenty-seven statements addressing epidemiology, pathophysiology, biomarkers, biological therapies, monitoring strategies, and response definitions were developed through iterative rounds. Consensus was defined as ≥80% agreement (scores 4-5 on a 5-point Likert scale).

Results

All 27 statements achieved consensus (agreement range: 82-100%; mean scores: 4.1-4.9). Complete consensus was reached on key issues, including the need for endotype-based therapy selection, the predominance of type 2 inflammation in severe pediatric asthma, the role of currently available biological therapies (omalizumab, mepolizumab, dupilumab, tezepelumab), multidimensional response assessment (clinical, functional, and biological), and the importance of patient and family engagement. Strong consensus also supported the use of Core Outcome Measures for Severe Asthma (COMSA) for monitoring, classification of responders/super-responders /non-responders, and the predictive value of selected biomarkers, including blood eosinophil counts (≥300 cells/µL), FeNO, and baseline oral corticosteroid dose.

Conclusions

This Delphi Consensus provides expert-endorsed, evidence-based recommendations for the management of severe pediatric asthma, emphasizing personalized selection of biological therapy guided by biomarkers and systematic response monitoring using standardized outcome measures.

Schlagwörter

Stichwörter der Autor:innen

Delphi Consensusadolescentsbiological therapybiomarkerschildrenresponse predictorssevere asthma

Autor:innen und Institutionen

  • Università della Campania.
  • Università di Pavia.
  • Università di Messina.
  • Ospedale di Erba.
  • Istituto G. Gaslini.
  • Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.

Zitieren

APA

Miraglia Del Giudice, M., Marseglia, G., Manti, S., Favuzza, F., Tosca, M. A., Ciprandi, G., & Licari, A. (2026). Delphi Consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP) on the management of severe asthma in children and adolescents. Multidisciplinary Respiratory Medicine, 21(Vol. 21 (2026)), 1095. https://doi.org/10.5826/mrm.2026.1095

Vancouver

Miraglia Del Giudice M, Marseglia G, Manti S, Favuzza F, Tosca MA, Ciprandi G, et al. Delphi Consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP) on the management of severe asthma in children and adolescents. Multidisciplinary Respiratory Medicine. 2026;21(Vol. 21 (2026)):1095. doi:10.5826/mrm.2026.1095

BibTeX
@article{MiragliaDelGiudice2026,
  author = {Miraglia Del Giudice, Michele and Marseglia, Gianluigi and Manti, Sara and Favuzza, Filippo and Tosca, Maria Angela and Ciprandi, Giorgio and Licari, Amelia},
  title = {Delphi Consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP) on the management of severe asthma in children and adolescents},
  journal = {Multidisciplinary Respiratory Medicine},
  year = {2026},
  volume = {21},
  number = {Vol. 21 (2026)},
  pages = {1095},
  doi = {10.5826/mrm.2026.1095}
}
Kostenlos starten →